Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06150157 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
A Phase 1 study of Neoplasms, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT06150157 is a Phase 1 study of Neoplasms that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 220 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06150157, a Phase 1 study of Neoplasms, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968 in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s) in part 2 (Cohort Expansion). For U.S. sites: the purpose of this study is to characterize the safety and to determine the RP2D(s) and optimal dosing schedule(s) of JNJ-88549968 in Part 1 and part 1b (Dose Escalation), and to characterize the safety of JNJ-88549968 at the RP2D(s) in Part 2 and part 2b (Cohort Expansion), when given as monotherapy in essential thrombocythemia (ET) or myelofibrosis (MF), and with ruxolitinib or momelotinib in MF only.
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG Momelotinib
- DRUG JNJ-88549968
Study Locations (20)
Other
- Hopital Saint Louis - Paris
- CH LYON SUD - Hematology - Pierre-Bénite
- Universitaetsklinikum der RWTH Aachen - Aachen
- Charite Campus Benjamin Franklin - Berlin
- Med. Universitatsklinik Essen - Essen
- Medizinische Hochschule Hannover - Hanover
- Universitaetsklinikum Heidelberg - Heidelberg
- Universitaetsklinikum Regensburg - Regensburg
New York
- Memorial Sloan Kettering Cancer Center - New York
- Montefiore Medical Center - The Bronx
California
- City of Hope - Duarte
Colorado
- UCHealth Cancer Care Anschutz Medical Campus University of Colorado Cancer Center - Aurora
Florida
- Moffit Cancer center - Tampa
Michigan
- University of Michigan - Ann Arbor
North Carolina
- Levine Cancer Institute - Charlotte
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2028-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06150157
The ClinicalTrials.gov registry entry for NCT06150157 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (86% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Ruxolitinib is the first listed.
NCT06150157 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, New York, California.
Frequently Asked Questions
What is clinical trial NCT06150157 about?
NCT06150157 is a clinical study titled "A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms". The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968 in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s) in part 2 (Cohort Expansion). For U.S. sites: the purpose o...
What is the current status of trial NCT06150157?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2023-12-20. Estimated completion is 2028-04-12.
What conditions does trial NCT06150157 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT06150157?
The interventions under investigation include: Ruxolitinib (DRUG), Momelotinib (DRUG), JNJ-88549968 (DRUG).
Who is sponsoring clinical trial NCT06150157?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06150157 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.